Stocktoria

Cardio Diagnostics Holdings, Inc. CDIO

Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2021-11-23 · LEI

Cardio Diagnostics Holdings, Inc. financials (annual)

Revenue
$901 $950 $17065 $34890 $14825 20212022202320242025
Net income
-$620448 -$4.7M -$8.4M -$8.4M -$6.5M 20212022202320242025
Free cash flow
-$6.2M -$5.2M -$5.9M 20212022202320242025

Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021
Revenue$14,825$34,890$17,065$950$901
R&D expense$641,212$227,966$145,182$40,448$31,468
Operating income-$6.5M-$8.4M-$7.2M-$4.5M-$620,448
Interest expense$14,801$18,640$6.7M
Income tax$0$0
Net income-$6.5M-$8.4M-$8.4M-$4.7M-$620,448
EPS (diluted)$-3.71$-9.35$-0.66$-1.51$-0.53
Operating cash flow-$5.7M-$5.0M-$5.7M-$5.1M-$585,291
Free cash flow-$5.9M-$5.2M-$6.2M
Cash & equivalents$0$0$0$0$0
Total assets$7.8M$10.6M$4.5M$6.2M$1.1M
Total liabilities$793,061$1.1M$1.5M$1.9M$33,885
Shareholders' equity$7.0M$9.6M$3.0M$4.3M$1.1M

Growth · year-over-year · Revenue CAGR 101.4%

MetricFY2025FY2024FY2023FY2022FY2021
Revenue growth-57.5%+104.5%+1696.3%+5.4%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.